Webdisclosure.com

Search

UCB (EBR:UCB) UCB Media Room: Acquisitions and Disposals of own shares

Directive transparence : information réglementée

09/04/2021 20:04
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg ** Acquisitions of own shares and Disposals of own shares ------------------------------------------------------------ Brussels (Belgium), 9 April 2021 =E2=80=93 20:00 (CEST) =E2=80=93 regulated= information Acquisitions of own shares In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi= ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB= =E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose= s certain information in relation to its Share Repurchase Program 2021.=C2= =A0 Under this program, UCB has requested a financial intermediary to repurchas= e up to 750 000 UCB shares on its behalf under the terms of an initial disc= retionary mandate agreement with validity until 25 June 2021, effective as = from 8 March 2021, to cover current and future obligations under UCB's Long= Term Incentive Plans for its personnel. In the framework of this Share Repurchase Program 2021, UCB repurchased 39 = 251 UCB shares on Euronext Brussels in the period from 2 April 2021 up to a= nd including 8 April 2021, as follows:=C2=A0 https://mb.cision.com/Public/18595/3322882/a151459482e290e9_800x800ar.png For consistency reasons, UCB confirms that during the same period, it has n= ot disposed of any UCB shares within the framework of the Long Term Incenti= ve Program of the UCB Group. This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://www.ucb.com/stories-media/Press-Releases) . Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 =C2=A0=C2=A0 =C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 8 400 peopl= e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.3 bi= llion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us = on Twitter: @UCB_news GenericFile 210409 - UCB Acquisitions and disposals of own shares ENG (https://mb.cisio= n.com/Public/18595/3322882/82d1138655428955.pdf) GenericFile 210409- Verwerving en vervreemding van eigen aandelen NED (https://mb.cisio= n.com/Public/18595/3322882/a058d4483015ada6.pdf) GenericFile 210409- Rachat et ali=C3=A9nation d actions propres FR (https://mb.cision.c= om/Public/18595/3322882/8103b70791c6920d.pdf) Image Chart 1 April 9 2021 (https://mb.cision.com/Public/18595/3322882/a151459482= e290e9_org.png)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x66120x1x6868579x24000= x6&Email=3Dregnews%40symexglobal.com.=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=